Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a Web-based dashboard for providers; PhreesiaPads, which are self-service intake tablets; and Arrivals Kiosks that are on-site kiosks. Its Phreesia Platform also provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; appointments solution for online appointments, reminders, and referral tracking; and patient activation solution that enables providers to communicate with their patients through surveys, announcements, messaging, and health campaigns. In addition, the company's Phreesia Platform offers clinical support solution, which collects clinical intake and PRO data for approximately 25 specialties; and life sciences solution to deliver targeted and clinically relevant marketing content to patients, as well as COVID-19 product offerings for managing COVID-19 vaccine delivery and identify vaccine-hesitant patients, screening for self-reported COVID-19 risk factors, enabling contactless check-in during in-person visits, and collecting intake information during telehealth visits. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was founded in 2005 and is headquartered in Raleigh, North Carolina.
IPO Year: 2019
Exchange: NYSE
Website: phreesia.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/26/2024 | $35.00 | Buy | Truist |
1/17/2024 | $30.00 → $32.00 | Neutral → Buy | DA Davidson |
1/3/2024 | $29.00 | Overweight | Barclays |
4/12/2023 | $37.00 | Overweight | Stephens |
1/4/2023 | $35.00 → $40.00 | Buy | Needham |
12/13/2022 | $40.00 | Neutral → Buy | Citigroup |
12/9/2022 | $31.00 → $34.00 | Mkt Perform → Outperform | SVB Leerink |
10/13/2022 | $25.00 | Neutral | DA Davidson |
9/16/2022 | $40.00 | Overweight | KeyBanc Capital Markets |
4/14/2022 | $45.00 | Buy | Guggenheim |
10-Q - Phreesia, Inc. (0001412408) (Filer)
8-K - Phreesia, Inc. (0001412408) (Filer)
8-K - Phreesia, Inc. (0001412408) (Filer)
8-K - Phreesia, Inc. (0001412408) (Filer)
10-Q - Phreesia, Inc. (0001412408) (Filer)
8-K - Phreesia, Inc. (0001412408) (Filer)
ARS - Phreesia, Inc. (0001412408) (Filer)
DEFA14A - Phreesia, Inc. (0001412408) (Filer)
DEF 14A - Phreesia, Inc. (0001412408) (Filer)
S-8 - Phreesia, Inc. (0001412408) (Filer)
Phreesia, a leader in patient intake, outreach and activation, is proud to announce that Audrey Gato, Vice President of Client Solutions, has been named to The Software Report's list of the Top 50 Women Leaders in SaaS of 2023. Honorees were chosen based on their leadership and contributions to the Software-as-a-Service industry. This is the sixth consecutive year a female leader from Phreesia has been named to the list. Previous Phreesia awardees include Allison Hoffman, General Counsel; Kristin Roberts, Vice President of Product Management; Kharen Hauck, Vice President of Marketing; Amy VanDuyn, Senior Vice President of Human Resources; and Sara DiNardo, Vice President of Client Solutio
SC 13G/A - Phreesia, Inc. (0001412408) (Subject)
SC 13G/A - Phreesia, Inc. (0001412408) (Subject)
SC 13G - Phreesia, Inc. (0001412408) (Subject)
SC 13G/A - Phreesia, Inc. (0001412408) (Subject)
SC 13G/A - Phreesia, Inc. (0001412408) (Subject)
SC 13G/A - Phreesia, Inc. (0001412408) (Subject)
SC 13G/A - Phreesia, Inc. (0001412408) (Subject)
SC 13G - Phreesia, Inc. (0001412408) (Subject)
SC 13G/A - Phreesia, Inc. (0001412408) (Subject)
SC 13G - Phreesia, Inc. (0001412408) (Subject)
4 - Phreesia, Inc. (0001412408) (Issuer)
4 - Phreesia, Inc. (0001412408) (Issuer)
4 - Phreesia, Inc. (0001412408) (Issuer)
4 - Phreesia, Inc. (0001412408) (Issuer)
4 - Phreesia, Inc. (0001412408) (Issuer)
4 - Phreesia, Inc. (0001412408) (Issuer)
4 - Phreesia, Inc. (0001412408) (Issuer)
4 - Phreesia, Inc. (0001412408) (Issuer)
4 - Phreesia, Inc. (0001412408) (Issuer)
4 - Phreesia, Inc. (0001412408) (Issuer)
Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal second quarter ended July 31, 2024. "We reached another very important milestone in Phreesia's evolution by crossing over to positive Free cash flow1 in the fiscal second quarter of 2025," said CEO and Co-Founder Chaim Indig. "We believe this milestone marks the start of a new era for Phreesia in which we are able to deploy internally generated cash to drive stakeholder value." Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q2 Fiscal Year 2025 Stakeholder Letter. Fiscal Second Quarter Ended July 31, 2024 Highlights Total revenue was
Collaboration aims to boost vaccination as coverage rates remain below pre-pandemic levels Phreesia, a leader in patient intake, outreach and activation, and the American Academy of Pediatrics (AAP), an organization of 67,000 pediatricians, have joined forces to increase measles, mumps and rubella (MMR) immunization by reaching parents and caregivers of eligible or soon-to-be eligible children at the point of care. The collaboration comes as immunization rates have dipped in some communities, pointing to a need to improve access to the vaccines that can help keep children healthy. Through a joint campaign that will run on Phreesia's digital intake platform, the organizations will engage
Phreesia Welcomes Former CEO of ENT and Allergy Associates Phreesia, a leader in patient intake, outreach and activation, is pleased to announce it has named Bob Glazer as a Strategic Advisor, leveraging his deep expertise and decades of experience in healthcare leadership to help ensure its offerings continue to meet the evolving needs of its clients. Glazer, whose career spans more than 45 years, is currently the President of Glazer Business Advisors, a consulting group that advises physician practices in areas such as physician recruitment, revenue cycle management, mergers and acquisitions, and strategic planning. Glazer spent 27 years as CEO of ENT and Allergy Associates (ENTA), th
Phreesia, Inc. (NYSE:PHR) ("Phreesia") today announced that it will release its fiscal second quarter 2025 financial results after the close of market trading on Wednesday, Sept. 4, 2024. Phreesia will issue a press release announcing its quarterly results and the company's quarterly stakeholder letter, both of which will be posted on its investor website at ir.phreesia.com. Phreesia will then hold a conference call to discuss its fiscal second quarter results starting at 5PM Eastern Time on the same day. To participate in the company's live conference call and webcast, please dial (800) 715-9871, or (646) 307-1963 for international participants, using conference code number 7404611, or v
New integration helps patients navigate through their entire care journey, from scheduling through follow-up Phreesia, a leader in patient intake, outreach and activation and a member of Oracle PartnerNetwork (OPN), today announced that Phreesia is available on Oracle Healthcare Marketplace and can be integrated with the Oracle Health Electronic Health Record (EHR). Oracle Healthcare Marketplace is a centralized repository of healthcare applications offered by Oracle and Oracle partners. This new collaboration strengthens Phreesia's existing integration with Oracle and provides expanded benefits for customers. Organizations that use the Oracle Health EHR will now be able to leverage Phr
A new survey in partnership with the National Kidney Foundation finds that discussions between patients and providers, and patient activation, are key to helping high-risk patients take preventive actions to manage their kidney health New research published in The American Journal of Accountable Care by Phreesia, in partnership with The National Kidney Foundation (NKF), found that even eight years after patients are diagnosed with diabetes and/or hypertension, many do not know that these conditions put them at high risk for chronic kidney disease (CKD). The study finds that discussions between a patient and their providers and patient activation play a significant role in detecting and pr
Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal first quarter ended April 30, 2024. "I am tremendously proud of our team's commitment to our growth and profitability1 objectives." said CEO and Co-Founder Chaim Indig. Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q1 Fiscal Year 2025 Stakeholder Letter. Fiscal First Quarter Ended April 30, 2024 Highlights Total revenue was $101.2 million in the quarter, up 21% year-over-year. Average number of healthcare services clients ("AHSCs") was 4,065 in the quarter, up 23% year-over-year. Healthcare services revenue per AHSC was $18
Phreesia, a leader in patient intake, outreach, and activation, has joined the MEDITECH Alliance Program, an ecosystem of partner organizations with proven, successful and interoperable solutions. Through the partnership, MEDITECH customers can leverage Phreesia to deliver a patient-driven registration experience, whether in a hospital-based or ambulatory care setting. Phreesia is joining the Alliance as an Innovator Partner, providing embedded solutions that can be included in MEDITECH as a Service (MaaS), and offering integrated solutions for all Expanse customers. MEDITECH's partnership with Phreesia began through the support of their Access eForms solution. Phreesia acquired Access eF
Phreesia is pleased to announce that the healthcare marketing industry trade publication PM360 has named Amy Patel, MPH, Director of Analytics, as one of its 2024 PM360 ELITE 100. Recognizing the most influential people in healthcare and life sciences, the PM360 ELITE 100 Awards honor individuals and teams who have made a significant impact on the industry. Patel, who has more than 15 years of experience in healthcare data, analytics and market research, was recognized in the awards' analytics category, which celebrates leaders who translate a multitude of research and numbers into actionable insights. As Director of Analytics at Phreesia, Patel is the leading force behind the delivery
Phreesia, a leader in patient intake, outreach and activation, has been selected by Modern Healthcare as one of the 2024 Best Places to Work in Healthcare. This is the eighth time Phreesia has been named to the list. "We're honored to once again be named one of Modern Healthcare's Best Places to Work in Healthcare," said Amy VanDuyn, Phreesia's SVP of Human Resources. "Phreesia's company culture is extremely important to us, as our employees are at the core of our overall success. We are very intentional in our efforts to support employees and amplify their voices, and winning this award showcases that our team members are engaged and committed to our mission, vision and values." This r
Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal second quarter ended July 31, 2024. "We reached another very important milestone in Phreesia's evolution by crossing over to positive Free cash flow1 in the fiscal second quarter of 2025," said CEO and Co-Founder Chaim Indig. "We believe this milestone marks the start of a new era for Phreesia in which we are able to deploy internally generated cash to drive stakeholder value." Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q2 Fiscal Year 2025 Stakeholder Letter. Fiscal Second Quarter Ended July 31, 2024 Highlights Total revenue was
Phreesia, Inc. (NYSE:PHR) ("Phreesia") today announced that it will release its fiscal second quarter 2025 financial results after the close of market trading on Wednesday, Sept. 4, 2024. Phreesia will issue a press release announcing its quarterly results and the company's quarterly stakeholder letter, both of which will be posted on its investor website at ir.phreesia.com. Phreesia will then hold a conference call to discuss its fiscal second quarter results starting at 5PM Eastern Time on the same day. To participate in the company's live conference call and webcast, please dial (800) 715-9871, or (646) 307-1963 for international participants, using conference code number 7404611, or v
Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal first quarter ended April 30, 2024. "I am tremendously proud of our team's commitment to our growth and profitability1 objectives." said CEO and Co-Founder Chaim Indig. Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q1 Fiscal Year 2025 Stakeholder Letter. Fiscal First Quarter Ended April 30, 2024 Highlights Total revenue was $101.2 million in the quarter, up 21% year-over-year. Average number of healthcare services clients ("AHSCs") was 4,065 in the quarter, up 23% year-over-year. Healthcare services revenue per AHSC was $18
Phreesia, Inc. (NYSE:PHR) ("Phreesia") today announced that it will release its fiscal first quarter 2025 financial results after the close of market trading on Thursday, May 30, 2024. Phreesia will issue a press release announcing its quarterly results and the company's quarterly stakeholder letter, both of which will be posted on its investor website at ir.phreesia.com. Phreesia will then hold a conference call to discuss its fiscal first quarter results starting at 5PM Eastern Time on the same day. To participate in the company's live conference call and webcast, please dial (888) 350-3437, or (646) 960-0153 for international participants, using conference code number 4000153, or visit
Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal fourth quarter and fiscal year ended January 31, 2024. "Phreesia ended fiscal year 2024 with strong momentum going into fiscal 2025. We facilitated more than 150 million patient visits in fiscal 2024, or more than one in ten patient visits across the U.S. We are confident that our solutions and our team position us for continued growth and a return to profitability1," said CEO and Co-Founder Chaim Indig. Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q4 Fiscal Year 2024 Stakeholder Letter. Fiscal Fourth Quarter Ended January 31, 2024 H
Phreesia, Inc. (NYSE:PHR) ("Phreesia") today announced that it will release its fiscal fourth quarter 2024 financial results after the close of market trading on Thursday, March 14, 2024. Phreesia will issue a press release announcing its quarterly results and the company's quarterly stakeholder letter, both of which will be posted on its investor website at ir.phreesia.com. Phreesia will then hold a conference call to discuss its fiscal fourth quarter results starting at 5PM Eastern Time on the same day. To participate in the company's live conference call and webcast, please dial (888) 350-3437, or (646) 960-0153 for international participants, using conference code number 4000153, or v
Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal third quarter ended October 31, 2023. "I am proud of our work during the third quarter to further our mission of helping patients take a more active role in their care," said CEO and Co-Founder Chaim Indig. Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q3 Fiscal Year 2024 Stakeholder Letter. Fiscal Third Quarter Ended October 31, 2023 Highlights Total revenue was $91.6 million in the quarter as compared to $73.1 million in the same period in the prior year, an increase of 25%. Average number of healthcare services clients ("AHSC
Phreesia, Inc. (NYSE:PHR) ("Phreesia") today announced that it will release its fiscal third quarter 2024 financial results after the close of market trading on Tuesday, December 5, 2023. Phreesia will issue a press release announcing its quarterly results and the company's quarterly stakeholder letter, both of which will be posted on its investor website at ir.phreesia.com. Phreesia will then hold a conference call to discuss its fiscal third quarter results starting at 5PM Eastern Time on the same day. To participate in the company's live conference call and webcast, please dial (888) 350-3437, or (646) 960-0153 for international participants, using conference code number 4000153, or vi
Phreesia, Inc. (NYSE:PHR) ("Phreesia" or the "Company") announced financial results today for the fiscal second quarter ended July 31, 2023. "I am incredibly pleased and proud of our team's accomplishments in the second quarter of fiscal year 2024. We continued to deliver excellent value for our clients and scale our business—all while helping patients take a more active role in their healthcare and achieve improved health outcomes," said CEO and Co-Founder Chaim Indig. Please visit the Phreesia investor relations website at ir.phreesia.com to view the Company's Q2 Fiscal Year 2024 Stakeholder Letter. Fiscal Second Quarter Ended July 31, 2023 Highlights Total revenue was $85.8 mill
Phreesia, a leader in patient intake, outreach and activation, is pleased to announce it has acquired Access eForms, an innovative electronic forms management and automation provider that helps hospitals across the country streamline workflows, improve compliance and deliver a better patient experience. Access eForms has a vast catalogue of content as well as deep expertise in the delivery of thousands of different forms used in healthcare settings, which has enabled them to quickly implement and retain clients. "Both Phreesia and Access eForms are focused on delivering value for healthcare organizations and helping them navigate staffing challenges, operate more efficiently, and make c
Truist initiated coverage of Phreesia with a rating of Buy and set a new price target of $35.00
DA Davidson upgraded Phreesia from Neutral to Buy and set a new price target of $32.00 from $30.00 previously
Barclays initiated coverage of Phreesia with a rating of Overweight and set a new price target of $29.00
Stephens initiated coverage of Phreesia with a rating of Overweight and set a new price target of $37.00
Needham reiterated coverage of Phreesia with a rating of Buy and set a new price target of $40.00 from $35.00 previously
Citigroup upgraded Phreesia from Neutral to Buy and set a new price target of $40.00
SVB Leerink upgraded Phreesia from Mkt Perform to Outperform and set a new price target of $34.00 from $31.00 previously
DA Davidson initiated coverage of Phreesia with a rating of Neutral and set a new price target of $25.00
KeyBanc Capital Markets initiated coverage of Phreesia with a rating of Overweight and set a new price target of $40.00
Guggenheim initiated coverage of Phreesia with a rating of Buy and set a new price target of $45.00
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Morgan Stanley cut the price target for Microchip Technology Incorporated (NASDAQ:MCHP) from $102 to $100. Morgan Stanley analyst Joseph Moore downgraded the stock from Overweight to Equal-Weight. Microchip Technology shares rose 3.9% to close at $95.98 on Wednesday. See how other analysts view this stock. Truist Securities lifted the price target for Astrana Health, Inc. (NASDAQ:ASTH) from $44 to $50. Truist Securities analyst Jailendra Singh upgraded the stock from Hold to Buy. Astrana Health sha
Keybanc analyst Scott Schoenhaus maintains Phreesia (NYSE:PHR) with a Overweight and lowers the price target from $27 to $25.
Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Phreesia (NYSE:PHR) in the last three months. The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 4 2 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 2 2 0 0 0 3M Ago 0 0 0 0 0 Insights from analysts' 12-month price targets are revealed, presenting an average target of $29.83, a high estimate of $34.00, and a low estimate of $28.00. A decline of 4.79% from the prior average price ta
Truist Securities analyst Jailendra Singh maintains Phreesia (NYSE:PHR) with a Buy and maintains $29 price target.
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. Here's the list of options activity happening in today's session: Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume PHR PUT TRADE NEUTRAL 06/21/24 $20.00 $570.0K 3.2K 3.1K LLY CALL SWEEP BEARISH 06/07/24 $850.00 $87.7
Truist Securities analyst Jailendra Singh maintains Phreesia (NYSE:PHR) with a Buy and lowers the price target from $35 to $29.
Shares of SentinelOne, Inc. (NYSE:S) shares fell sharply during Friday's session after the company posted mixed first-quarter results. SentinelOne reported quarterly losses of 23 cents per share, which missed the analyst consensus estimate of losses of 5 cents by 360%. Quarterly sales came in at $186.4 million which beat the analyst consensus estimate of $181.09 million by 2.93%, according to data from Benzinga Pro. SentinelOne shares dipped 15.9% to $16.35 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Novo Integrated Sciences, Inc. (NASDAQ:NVOS) shares jumped 130.6% to $1.04 after the company approved a $5 million stock repurchase. The comp
Canaccord Genuity analyst Richard Close maintains Phreesia (NYSE:PHR) with a Buy and lowers the price target from $37 to $34.
Stephens & Co. analyst Jeff Garro reiterates Phreesia (NYSE:PHR) with a Overweight and maintains $28 price target.
JMP Securities analyst Joe Goodwin reiterates Phreesia (NYSE:PHR) with a Market Outperform and maintains $30 price target.